SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly update sharply raised its revenue and gross-margin outlook on stronger AI-platform demand, driving a major after-hours rally. Many traders welcomed the improved outlook and anticipated further gains or short covering, while others questioned whether the momentum would hold given the companys volatile history and lingering trust concerns.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly results beat expectations, with rapid growth in its AI compute business and an aggressive buildout outlook driving strong enthusiasm. Traders are also debating whether the ambitious growth targets justify the valuation given heavy capital spending and uncertain execution.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly profit beat expectations, but softer forward guidance and a reduced advertising-revenue outlook have intensified concerns about slowing growth and weighed on the shares. Traders are debating whether the ad business and content strategy can revive momentum, with many bearish while some view the selloff as overdone and are buying the dip.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

A sharp, high-volume rebound has put WULF in focus, with traders crediting CEO Paul Pragers CNBC interview and his explanation of the companys powered-shell model: leasing data-center infrastructure and power rather than buying GPUs. Bulls see its AI/HPC contracts and buildout as differentiating it from debt-heavy neocloud peers, while skeptics call the move a relief bounce and remain concerned about financing, execution, and the broader sector selloff.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports RAP-219 Phase 2 trial in acute bipolar mania met its primary and secondary endpoints, drawing attention to the drugs potential beyond epilepsy. Traders are split: some view the results as validation of the pipeline, while others cite the modest placebo-adjusted benefit and higher agitation-related discontinuations as reasons for caution as the early gains faded.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCN is drawing attention amid a price rebound and breakout chatter, with bullish traders pointing to Zebecs reported payroll, card and network adoption, including its Stellar deployment. Skeptics counter that the token has struggled to sustain gains and say adoption must translate into stronger usage, volume and token demand.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgicals quarterly results beat expectations, but shares sold off sharply as traders focused on a narrower procedure-growth outlook, planned pricing reductions, and a litigation settlement. The community is split between viewing the reaction as an overdone dip-buying opportunity and seeing the outlook and pricing pressures as reasons for caution.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to Middle East shipping and infrastructure threats that raise fears of oil-supply disruptions. Bulls see the geopolitical risk premium supporting crude, while bears expect it to unwind if shipping flows normalize or peace talks progress, fueling debate over the funds volatile moves.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Anticipation of Reddits upcoming quarterly results is driving discussion, with traders watching for evidence that ad growth and AI data licensing can support the stock. Bulls expect strong results to break its recent range, while bears point to insider selling, valuation concerns, and frustrating price action.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is drawing attention for outperforming the cap-weighted S&P 500 as gains spread across more constituent stocks while mega-cap technology lagged. Traders view the strength as evidence of broader participation and rotation beyond tech, though some caution that the improvement may not last.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This OGE Energy Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

Analysts upgraded Alumis, Sirius XM, OGE Energy, revising their price targets and outlooks.read more...

ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?

Equity

The selloff followed topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus, or SLE, a chronic autoimmune disease in which the body's immune system mistakenly attacks healthy tissues. 


Why Is Alumis Stock Falling Tuesday?

Alumis (ALMS) stock drops over 50% after Phase 2b lupus trial misses overall endpoints, but sub-group data shows promise.read more...

Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates

Alumis releases long-term data for psoriasis drug envudeucitinib, boasting top skin clearance rates ahead of a Q4 FDA filing with FDA.read more...

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of +17.95% and -1.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter

Key PointsDeep Track Capital bought 6,772,595 shares of Alumis last quarter; the estimated transaction value was $169.31 million (based on average prices...

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter

Key PointsCormorant bought 313,645 additional Alumis shares in the first quarter; the estimated trade size was $7.84 million (using average prices in the quarter...

Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back

Key PointsOmega Fund Management sold 411,968 shares of Alumis; the estimated trade value is $10.3 million (based on quarterly average price...

This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Top analysts changed outlook on top names. See all rating changes on analyst ratings page. Check out analysts' views on ALMS stock.read more...

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>The trial missed its main goals but showed benefits in a particular patient subgroup.&nbsp;</li><li>Chief Medical Officer Jörn Drappa called the subgroup effect “highly compelling” in a disease that still lacks a targeted oral therapy.</li><li>Alumis remains on track to file for U.S. approval of envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter.</li></ul><p>Shares of Alumis Inc. (ALMS) collapsed 57% on Tuesday, clocking its worst day ever since its mid-2024 IPO, after the biotech said its mid-stage lupus study missed its main goals.</p><p>The selloff followed topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus, or SLE, a chronic autoimmune disease in which the body's immune system mistakenly attacks healthy tissues, causing widespread inflammation and damage across multiple organs.</p><h2 class="st-heading-2">Trial Missed Overall Goals</h2><p>The 48-week study enrolled 408 patients who received one of three doses of the drug or placebo. It failed its primary goal — a standard composite measure of overall disease activity — and key secondary measures of response and skin improvement in the full patient group.</p><p>A planned look at a subgroup told a different story. Patients with a common and well-defined lupus subtype posted stronger results on those same measures. Alumis said that group was unexpectedly under-represented in the trial, which weakened the overall readout. The drug was generally well tolerated, with no new safety issues.</p><h2 class="st-heading-2">Company Still Plans Next Steps</h2><p>Chief Medical Officer Jörn Drappa called the subgroup effect “highly compelling” in a disease that still lacks a targeted oral therapy. The company plans to meet with regulators about a late-stage program focused on that patient group.</p><p>CEO Martin Babler said the data also support studying the drug in certain other diseases. Alumis remains on track to file for U.S. approval of envudeucitinib for moderate-to-severe plaque psoriasis in the fourth quarter, following successful late-stage trials.</p><h2 class="st-heading-2">Analysts Cut Targets, Keep Buy Ratings</h2><p>Wells Fargo cut its price target on ALMS to $25 from $51 and kept an Overweight rating. The firm said the drop “seems overdone,” arguing there is a “credible path” to a Phase 3 lupus study and that the stock’s current value assigns little credit to the psoriasis program, which it sees as having a high chance of approval.</p><p>Baird, meanwhile, lowered its target to $27 from $35 and kept an Outperform rating.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around ALMS stock rose from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume increased from ‘low’ to ‘extremely high’ level.</p><p>“Feels like the market's overreacting when it's really more of a "wrong patients, right drug" problem,” a Stocktwits user wrote, noting that the company only needs to screen the right people on the late-stage trial.</p><p><stembedurl>https://stocktwits.com/HarmonyPioneer67/message/663389027</stembedurl></p><p>Another voiced optimism for a buyout, noting that company CEO Martin Babler sold his previous company, Principia Biopharma, to Sanofi in 2020. “Lilly gonna jump on this one,” the user said.</p><p><stembedurl>https://stocktwits.com/murphylaw/message/663372618</stembedurl></p><p><a href="https://stocktwits.com/symbol/ALMS">ALMS stock </a>has fallen about 3% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-hits-fresh-52-week-low-as-wall-street-slashes-price-targets-citing-slow-demand/cZso6ghRJMw">NIO Stock Hits Fresh 52-Week Low As Wall Street Slashes Price Targets Citing Slow Demand</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Alumis logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The selloff followed topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus, or SLE, a chronic autoimmune disease in which the body's immune system mistakenly attacks healthy tissues. 

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.70
Prev Close	$6.34
Open	$6.33
Dividend Yield	0.00%
50-Day Moving Average	$12.73
Beta	1.16
Avg. Volume	5.05M
PE Ratio	-1.76

52-Week High	$31.35
52-Week Low	$4.37
Market Capitalization	$846.36M
EPS (Annual)	-$2.86
Price to Book	1.90
Revenue Per Employee	$107,366.07

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALMS Fundamentals